CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors sec ...

Core Insights - Wave Life Sciences has regained full rights to WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK, allowing the company to advance its development strategy independently [1][2] - The company plans to engage with the FDA regarding a potential accelerated approval pathway for WVE-006, with regulatory feedback expected by mid-2026 [1][2] - Wave anticipates data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial in the first quarter of 2026, with additional data from the 600 mg cohorts expected later in 2026 [1][2] Company Developments - Wave Life Sciences is focused on RNA medicines and has a diversified pipeline that includes clinical programs for AATD, obesity, Duchenne muscular dystrophy, and Huntington's disease [6] - The company has a strong cash runway, expecting to fund operations into the third quarter of 2028, not including potential future milestone payments from its collaboration with GSK [4] - Wave's collaboration with GSK continues to expand, with a fourth program selected for advancement, potentially leading to up to $2.8 billion in milestone payments and tiered royalties [3] Clinical Trial Progress - WVE-006 has shown promising interim data, achieving key treatment goals for AATD, including significant AAT production during acute phase response [2] - The ongoing RestorAATion-2 clinical trial is on track, with data from the 400 mg cohort expected in early 2026 and further data from the 600 mg cohort anticipated later that year [1][2]

Core Insights - The article discusses the collaboration between Syensqo and Vertical Aerospace, focusing on the supply of high-performance composite materials for the VX4 electric vertical takeoff and landing aircraft, which aims for certification and commercial operation by 2028 [2][3]. Group 1: Company Collaborations - Syensqo (formerly Solvay) has entered a long-term partnership with Vertical Aerospace to supply composite materials and adhesives for the VX4 aircraft [2]. - The VX4 aircraft is designed to be zero-emission and can carry four passengers, with approximately 1,500 pre-orders from major airlines [3]. Group 2: Material Innovations - Syensqo's composite materials, including brands like CYCOM®, PRISM®, AeroPaste®, and FusePly™, are highlighted for their unique properties that enhance performance in advanced air mobility (AAM) applications [3]. - The APC PEKK/PEEK thermoplastic composite materials offer significant weight and cost advantages for innovative urban air mobility (UAM) and AAM applications [4]. - FusePly™ technology improves performance and manufacturing speed while reducing the need for rivets and fasteners in AAM applications [4]. - KetaSpire® PEEK and Evolite® PPS thermoplastic composites are noted for their high strength-to-weight ratio, chemical resistance, and superior mechanical performance [4].

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].

Core Viewpoint - Wave Life Sciences Ltd. has initiated a public offering of $250 million in ordinary shares and pre-funded warrants, with an option for underwriters to purchase an additional 15% of the total offering [1][2]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health. The company utilizes its PRISM® platform, which integrates various modalities and innovations in chemistry to develop treatments for both rare and common disorders [5]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs leveraging its RNA therapeutics toolkit [5]. Offering Details - The public offering will be conducted by Jefferies, Leerink Partners, and BofA Securities as joint book-running managers [2]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the final terms [2]. - A prospectus and related supplement will be filed with the SEC, detailing the terms of the offering [3].

Core Insights - Wave Life Sciences Ltd. is set to announce interim data from the Phase 1 INLIGHT clinical trial for WVE-007, an investigational treatment for obesity, on December 8, 2025 [1] - The company utilizes its proprietary SpiNA design in the development of WVE-007, which targets INHBE mRNA linked to obesity [3] Group 1: WVE-007 Overview - WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, which has shown potential in improving body composition and reducing the risk of type 2 diabetes and cardiovascular disease [3] - Preclinical studies indicate that WVE-007 can lead to adipocyte shrinkage, reduced inflammation, and improved insulin sensitivity [3] - When used in conjunction with semaglutide, WVE-007 demonstrated a doubling of weight loss in mice and prevented weight regain after stopping semaglutide [3] Group 2: INLIGHT Clinical Trial - The INLIGHT trial is a first-in-human study evaluating WVE-007 in adults with overweight or obesity, focusing on safety, tolerability, and various health metrics [4] - The trial employs a 3:1 active to placebo ratio and is being conducted at multiple sites, including locations in the US [4] Group 3: Company Background - Wave Life Sciences is a biotechnology firm dedicated to RNA medicines, with a diverse pipeline addressing conditions such as obesity, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy [5] - The company's PRISM® platform integrates various RNA-targeting modalities, enabling innovative treatments for both rare and common diseases [5] - Wave Life Sciences is headquartered in Cambridge, MA, and aims to transform human health through scientific breakthroughs [5]

Core Insights - Wave Life Sciences Ltd. is set to host a live webcast and conference call on November 10, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide business updates [1] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3] - The company's RNA medicines platform, PRISM®, integrates various modalities and chemistry innovations to address both rare and common disorders [3] - Wave's pipeline includes clinical programs targeting alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - The company is headquartered in Cambridge, MA, and emphasizes its mission to "Reimagine Possible" in the realm of human health [3]

Core Insights - Wave Life Sciences Ltd. is hosting a virtual Research Day on October 29, 2025, at 10:00 a.m. ET to discuss its advancements in RNA medicines [1][3] - The company will also participate in several investor conferences, including the Bernstein 2nd Annual Healthcare Forum and the Stifel Virtual Cardiometabolic Forum [2] Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [4] - The company's RNA-targeting modalities include editing, splicing, RNA interference, and antisense silencing, which enhance its capabilities in developing therapeutic candidates [4] - Wave's pipeline includes clinical programs targeting alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [4]

Core Viewpoint - Wave Life Sciences Ltd. is set to host a live webcast and conference call on July 30, 2025, to discuss its second quarter 2025 financial results and provide business updates [1]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3]. - The company's RNA medicines platform, PRISM®, integrates various modalities and chemistry innovations to address both rare and common disorders [3]. - Wave's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [3]. - The company is headquartered in Cambridge, MA, and emphasizes its mission to "Reimagine Possible" in the context of human health [3]. Event Details - The webcast and conference call will be accessible via the "Investor Events" section on the Wave Life Sciences website [2]. - An archived version of the webcast will be available after the live event [2].

Company Overview - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines to transform human health [3] - The company utilizes its RNA medicines platform, PRISM®, which integrates various modalities and chemistry innovations to address both rare and common disorders [3] - Wave's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [3] Upcoming Events - Wave Life Sciences will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to review Q1 2025 financial results and provide business updates [1] - The event can be accessed via the "Investor Events" section on the company's website [2] - An archived version of the webcast will be available on the company's website following the live event [2]